Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis
Table 2
Clinical and laboratory characteristics in patients with different neutrophil-to-lymphocyte ratio (NLR) at admission.
Group A
Group B
Group C
(NLR ≤ 2.0, )
(2.0 < NLR < 5.0, )
(NLR ≥ 5.0, )
Age (y)
53.0 ± 10.1
53.5 ± 12.7
52.8 ± 10.7
0.946
Gender (male/female)
47/14
47/9
24/7
0.611
Total protein (g/L)
61.7 ± 6.4
62.6 ± 8.0
56.8 ± 10.4
0.004
Albumin (g/L)
29.6 ± 5.9
32.0 ± 5.9
28.9 ± 5.4
0.023
ALT (U/L)
44.5 ± 44.1
59.4 ± 93.2
65.2 ± 72.5
0.379
AST (U/L)
57.5 ± 39.0
81.0 ± 118.4
94.6 ± 98.5
0.182
INR
1.46 ± 0.29
1.50 ± 0.48
1.56 ± 0.41
0.471
Creatinine (mmol/L)
74.9 ± 19.9
77.4 ± 43.4
100.4 ± 61.1
0.013
Total bilirubin (μmol/L)
79.8 ± 91.5
98.3 ± 107.8
123.3 ± 162.9.37
0.233
MELD score
12.46 ± 1.73
13.88 ± 6.15
16.14 ± 7.84
0.033
White blood cell count (×109/L)
3.51 ± 6.22
4.62 ± 2.09
10.00 ± 8.66
<0.001
Neutrophil count (×109/L)
1.63 ± 0.79
3.00 ± 1.38
8.22 ± 7.36
<0.001
Lymphocyte count (×109/L)
1.33 ± 0.71
0.95 ± 0.45
0.88 ± 0.81
0.001
Ascites (yes/no)
40/21
45/11
22/9
0.200
HRS (yes/no)
8/53
10/46
11/20
0.035
HE (yes/no)
0/61
1/55
2/29
—
Mortality (yes/no)
3/58
6/50
7/24
0.036
Data are expressed as or mean ± SD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte ratio; MELD score, model for end-stage liver disease score; HE, hepatic encephalopathy; HRS, hepatorenal syndrome.
